IQVIA HOLDINGS INC.

(IQV)
  Report
Delayed Nyse  -  05/20 04:04:30 pm EDT
201.83 USD   +0.04%
05/05TikoMed AB and IQVIA Announce Strategic Collaboration for the Development of TikoMed's Lead Drug Platform Candidate ILB®
CI
05/04TRANSCRIPT : IQVIA Holdings Inc. - Special Call
CI
04/29IQVIA Holdings Shares Rise Midday Following Piper Upgrade, Target Increase
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mizuho Securities Adjusts IQVIA Holdings PT to $300 From $290, Maintains Buy Rating

12/20/2021 | 09:00am EDT


© MT Newswires 2021
All news about IQVIA HOLDINGS INC.
05/05TikoMed AB and IQVIA Announce Strategic Collaboration for the Development of TikoMed's ..
CI
05/04TRANSCRIPT : IQVIA Holdings Inc. - Special Call
CI
04/29IQVIA Holdings Shares Rise Midday Following Piper Upgrade, Target Increase
MT
04/29Piper Sandler Lifts IQVIA Holdings to Overweight From Neutral, Price Target to $255 Fro..
MT
04/28IQVIA HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
04/28Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 20..
CI
04/28Stifel Nicolaus Adjusts Price Target for IQVIA Holdings to $271 From $297, Maintains Bu..
MT
04/28KeyBanc Adjusts IQVIA Holdings' Price Target to $250 from $290, Keeps Overweight Rating
MT
04/28IQVIA HOLDINGS INC. : SEC Filing 10Q-1
CO
04/28IQVIA HOLDINGS INC. : SEC Filing 10Q-1
CO
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 14 632 M - -
Net income 2022 1 291 M - -
Net Debt 2022 10 188 M - -
P/E ratio 2022 30,2x
Yield 2022 -
Capitalization 38 202 M 38 202 M -
EV / Sales 2022 3,31x
EV / Sales 2023 2,95x
Nbr of Employees 82 000
Free-Float 73,3%
Chart IQVIA HOLDINGS INC.
Duration : Period :
Iqvia Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 201,83 $
Average target price 266,94 $
Spread / Average Target 32,3%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
Jeffrey A. Spaeder Chief Medical & Scientific Officer
Costa Panagos President-Research & Development Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.-28.46%38 202
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567
ALNYLAM PHARMACEUTICALS, INC.-23.72%15 980